Sprint Bioscience: Sprint Bioscience enters a VADA licensing agreement - Redeye
Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals. We will return with a more in-depth take in a research update.
ANNONS
Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals. We will return with a more in-depth take in a research update.